Back to search

Boston University

Exploration of the pathogenesis and emerging therapeutic strategies in atopic dermatitis

Abstract

dc:description.abstract

Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin disease that significantly impacts the quality of life in 20% of children and 1-3% of adults globally. The disease is defined by a vicious itch-scratch cycle resulting in characteristic dry, scaly, and erythematous lesions of the skin. Key drivers of this cycle include mutations in the filaggrin (FLG) gene, hyperactivity of the Type 2 (Th2) immune pathway, and dysbiosis of the skin microbiome favoring Staphylococcus aureus. Overall, the pathogenesis of atopic dermatitis is multifactorial, involving genetic predisposition, environmental influences, and immune dysregulation. The complex interplay among these factors poses a challenge for precise diagnosis and treatment. A broad selection of current atopic dermatitis literature was reviewed to evaluate current and novel therapeutics in treating AD. Historically, standard of care treatments, including emollients and topical anti-inflammatory agents, have been effective in restoring the skin barrier function and alleviating the symptoms by increasing skin hydration. For example, emollients contain many hydrating factors that allow for water retention of the skin barrier. Emollients serve as preventative treatment and have limitations in their ability to restore the skin barrier when AD symptoms progress. Often regarded as the first line of treatment of AD, topical corticosteroids work towards reducing expression of pro-inflammatory mediators that are overexpressed as part of the disease course. AD patients with mild disease have found benefits with use the calcineurin inhibitor, cyclosporine, and immunosuppressants, azathioprine and methotrexate. However, due to the clinical heterogeneity of the disease and its variable severity, these conventional treatments are proving to be insufficient in treating the disease alone. Recent advances in therapeutic research have shifted towards targeted immunomodulatory strategies, including agents that inhibit key signaling pathways such as the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. One of the most studied biologics for treating AD is dupilumab, a targeted therapy that inhibits the expression of key inflammatory cytokines Interleukin (IL)-4 and IL-13. Across numerous clinical trials, AD patients have reported significant relief in symptoms after dupilumab treatment correlated with a great reduction in scoring criteria. Nonetheless, AD pathogenesis encompasses a broad spectrum of inflammatory cytokines and mediators, indicating the need to develop therapeutics that address these alternative effectors. Following the recognition of this issue, several new therapeutics have been introduced to the market for treating AD, many of which have been previously approved for the treatment of other inflammatory diseases. These include the first approved pan-JAK inhibitor, delgocitinib; the JAK1/3 inhibitor, tofacitinib; and the JAK1 inhibitor, abrocitinib. Overall, JAK inhibitors have shown to be effective in treating moderate to severe AD with significant improvement in skin lesions as soon as four weeks after initiating treatment. The last emerging therapeutic discussed in this review is tapinarof, an aryl hydrocarbon receptor (AHR) agonist that helps modulate the effects of the AHR and aid in skin barrier repair. Continued exploration of the immunologic mechanisms underlying AD will provide critical insight into improved therapeutic approaches. Although research in these emerging therapies remains limited, current evidence suggests that they demonstrate promising efficacy in the management of more severe forms of AD and are generally well tolerated, with a low incidence of serious adverse events reported in clinical trials.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Zheng, Crystal
Advisor dc:contributor.advisor
  • Bragdon, Beth

Subjects

dc:subject × 1

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/53793

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Zheng, Crystal. Exploration of the pathogenesis and emerging therapeutic strategies in atopic dermatitis. masters thesis, Boston University, 2026. https://hdl.handle.net/2144/53793